Psilocybin Therapy in Canada: What's Available, What It C...

Psilocybin therapy in Canada is moving from clinical trials into real-world practice faster than the legislation can keep pace with. Psilocybin-assisted therapy is becoming a genuine option for Canadians — not fully legal in the conventional sense, but more accessible than at any point in the past 50 years. Here’s an honest picture of what exists, who can access it, and what it actually involves.

Psilocybin Therapy in Canada: Clinics, Access, and What to Expect

Health Canada’s Section 56 of the Controlled Drugs and Substances Act allows for exemptions from drug scheduling laws for specific medical or scientific purposes. Since 2020, hundreds of Canadians have received individual Section 56 exemptions to use psilocybin therapeutically.

In August 2022, Health Canada expanded access by allowing regulated healthcare practitioners to apply for exemptions on behalf of their patients, without patients having to apply individually. This significantly reduced the bureaucratic burden and opened access to anyone whose doctor or therapist is willing to apply.

Conditions that have qualified for exemptions include treatment-resistant depression, end-of-life distress, PTSD, and substance use disorders. The clinical evidence supporting psilocybin for these conditions is among the strongest seen for any psychiatric intervention in decades — which is why Health Canada has been willing to move.

Where to Access Psilocybin Therapy in Canada

Several Canadian clinics now offer legal psilocybin-assisted therapy under the Section 56 framework. They vary in approach, cost, and which conditions they treat:

Numinus Wellness (Vancouver, Calgary, Toronto) — one of the first licensed psilocybin therapy providers in Canada. Offers both ketamine and psilocybin programs depending on patient eligibility.
TheraPsil (Victoria) — the organization that helped establish the Section 56 pathway. Works primarily with end-of-life patients and has assisted hundreds of Canadians with the exemption process.
Field Trip Health — offers psychedelic-assisted therapy through ketamine currently, with psilocybin programming developing.
Roots to Thrive (Nanaimo) — group-format psilocybin therapy under Section 56 exemption.

What a Psilocybin Therapy Session Looks Like

Legitimate psilocybin-assisted therapy follows a three-phase model that the research has validated:

Preparation (1–3 sessions): Meeting with a therapist to discuss your history, intention, and what might arise. Building trust with the therapist who will be present during your session. Addressing any contraindications (personal or family history of psychosis, current medication interactions).

The medicine session: Typically 6–8 hours. You’re in a clinical but comfortable space — a bed or recliner, an eye mask, carefully selected music. A therapist or guide is present throughout but mostly non-directive. The dose is usually 25mg synthetic psilocybin (roughly equivalent to 3–3.5g of dried mushrooms). You’re encouraged to surrender to the experience and trust the process.

Integration (2–4 sessions): Processing what arose during the session with your therapist. This phase is often cited by researchers as the most therapeutically important — the session creates material, integration makes it meaningful.

What It Costs

Legal psilocybin therapy in Canada is expensive and not covered by provincial health insurance. A full program — preparation, medicine session, and integration — typically costs $3,000–$8,000 depending on the clinic and number of sessions. Some clinics offer income-based sliding scale pricing.

The cost is high partly because of the time involved (a therapist is present throughout an 8-hour session) and partly because of the additional administrative overhead of operating under a Section 56 exemption.

Self-Directed Use vs Therapeutic Context

Most Canadians who use psilocybin do so outside the clinical framework — purchasing mushrooms through online vendors and creating their own set and setting. The research makes clear that context matters enormously: psilocybin produces different outcomes depending on the preparation, the environment, and the support structure around the experience.

This doesn’t mean therapeutic benefit requires a clinical setting. Many people report meaningful psychological shifts from well-prepared self-directed sessions. What the clinical model adds is professional support for processing difficult material, medical oversight, and the preparation and integration frameworks that the research shows amplify and sustain outcomes.

If you’re considering self-directed use for mental health purposes, the research overview is worth reading, and the beginner’s guide covers the practical preparation that the clinical literature consistently identifies as important regardless of context.

The Direction of Travel

Psilocybin therapy in Canada is following the trajectory of ketamine before it — moving from experimental to acknowledged to standard care faster than most expected. Australia approved psilocybin for treatment-resistant depression in 2023. Oregon launched regulated psilocybin services in 2023. Canada’s regulatory environment is likely 3–5 years behind these models, but moving in the same direction.

For Canadians who can’t access or afford clinical therapy, the exemption system continues to expand, some therapists are quietly supporting self-directed use as part of broader treatment plans, and the harm reduction and preparation resources available online have improved substantially as the research base has grown.